Balance Sheet Dive: Adma Biologics Inc (ADMA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $20.29 in the prior trading day, Adma Biologics Inc (NASDAQ: ADMA) closed at $20.18, down -0.54%. In other words, the price has decreased by -$0.54 from its previous closing price. On the day, 2.75 million shares were traded. ADMA stock price reached its highest trading level at $20.41 during the session, while it also had its lowest trading level at $19.83.

Ratios:

Our goal is to gain a better understanding of ADMA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 53.30 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 70.58. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 6.87. In the meantime, Its Debt-to-Equity ratio is 0.75 whereas as Long-Term Debt/Eq ratio is at 0.74.

On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.

Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 09 ’24 when Guiheen Lawrence P. sold 9,000 shares for $18.47 per share. The transaction valued at 166,189 led to the insider holds 153,941 shares of the business.

Guiheen Lawrence P. bought 9,000 shares of ADMA for $146,340 on Sep 09 ’24. On Aug 30 ’24, another insider, Kestenberg-Messina Kaitlin M., who serves as the COO and SVP, Compliance of the company, sold 24,150 shares for $16.90 each. As a result, the insider received 408,050 and left with 449,088 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 4703614976 and an Enterprise Value of 4756765696. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 143.53, and their Forward P/E ratio for the next fiscal year is 30.81. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.24 while its Price-to-Book (P/B) ratio in mrq is 24.98. Its current Enterprise Value per Revenue stands at 14.404 whereas that against EBITDA is 50.022.

Stock Price History:

Over the past 52 weeks, ADMA has reached a high of $20.58, while it has fallen to a 52-week low of $3.06. The 50-Day Moving Average of the stock is 19.12%, while the 200-Day Moving Average is calculated to be 104.79%.

Shares Statistics:

The stock has traded on average 4.80M shares per day over the past 3-months and 4746330 shares per day over the last 10 days, according to various share statistics. A total of 226.06M shares are outstanding, with a floating share count of 225.20M. Insiders hold about 3.38% of the company’s shares, while institutions hold 77.90% stake in the company. Shares short for ADMA as of 1726185600 were 12421213 with a Short Ratio of 2.59, compared to 1723680000 on 9015280. Therefore, it implies a Short% of Shares Outstanding of 12421213 and a Short% of Float of 5.4899998.

Most Popular